Regenetech Achieves a 60-Fold Increase of Adult Stem Cells Through Its cellXpansion(TM) Process

Regenetech, Inc., the adult stem cell company which has built upon
NASA licensed technology, announced that the Company has significantly
augmented its cell multiplication capabilities for CD34+38- peripheral
blood progenitor cells (adult stem cells). These new results were
achieved through the continued development of cell culture conditions
for Regenetech's proprietary and patented Intrifuge(TM)
cellXpansion(TM) technology. Developing a significant and reliable
technology for adult stem cell growth and multiplication currently
represents one of the most significant barriers preventing more
widespread autologous adult stem cell therapeutic use.

Under the new, improved growth conditions, the number of adult
stem cells increased by 50-200 times the original number, an
achievement accomplished in as few as 6 days. Compared to other
serum-free media, the optimized Regenetech formulation yields
considerably higher cell numbers than were previously achievable,
significantly enhancing the market competitiveness and commercial
potential of the cellXpansion(TM) technology.

David Bonner, CEO of Regenetech, said: "We are delighted with the
progress that the team has made. This is a significant step forward
for our technology, and we are excited about what it will allow us to
do in the future in terms of providing doses of adult stem cells to
help patients. This development will demonstrate to the wider industry
that adult stem cells can be expanded in three-dimensional conditions
to achieve therapeutic doses for autologous use. We believe this
technology will have a significant impact on many treatments and will
bring us even closer to realizing the potential for treating diseases
through the use of expanded adult stem cells."

Regenetech's technology uses NASA based technologies which were
discovered in space experiments in which adult stem cells and tissue
are grown in a weightless three-dimensional environment. The stem
cells are harvested from the patient's own blood and multiplied in
Regenetech's Intrifuge(TM) Bioreactor in order to achieve therapeutic
quantities for re-introduction into the original patient. The
technology is capable of producing therapeutic quantities of adult
stem cells rapidly and at reasonable cost. Regenetech is licensing the
technology broadly to ensure the technology is available for general
use by researchers and commercial operators.

For more information about Regenetech, contact
twang@regenetech.com or visit www.regenetech.com. For licensing
opportunities, contact rclark@regenetech.com.

Forward Looking Statements: The Private Securities Litigation
Reform Act of 1995 provides a "safe harbor" for certain
forward-looking statements.